Torrent Pharmaceuticals is currently trading at Rs. 3365.00, up by 20.60 points or 0.62% from its previous closing of Rs. 3344.40 on the BSE.

The scrip opened at Rs. 3419.95 and has touched a high and low of Rs. 3474.60 and Rs. 3343.35 respectively. So far 24415 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3589.95 on 10-Oct-2024 and a 52 week low of Rs. 2760.30 on 01-Jul-2024.

Last one week high and low of the scrip stood at Rs. 3474.60 and Rs. 3139.50 respectively. The current market cap of the company is Rs. 114198.26 crore.

The promoters holding in the company stood at 68.31%, while Institutions and Non-Institutions held 24.66% and 7.03% respectively.

Torrent Pharmaceuticals has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR, a leading global investment firm, at an equity valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities. The transaction plays a key role in the company’s ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities.

The transaction will be executed in two phases. In the first phase, the company will acquire 46.39% equity stake of JB Pharma through a share purchase agreement (SPA) at a consideration of Rs 11,917 crore (Rs 1,600 per share) followed by a mandatory open offer to acquire up to 26% of JB Pharma shares from public shareholders at an open offer price of Rs 1,639.18 per share. In addition to the above, the company has also expressed its intent to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same price per share as KKR. In the second phase of transaction, both companies will merge through a scheme of arrangement. As per the approval given by the Board of Directors of both companies, upon merger of JB Pharma with Torrent, every shareholder holding 100 shares in JB Pharma shall receive 51 shares of Torrent.

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.